Navigation Links
Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone
Date:1/27/2010

BANGALORE, India, January 27 /PRNewswire-FirstCall/ -- Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd., and Endo Pharmaceuticals ( ENDP)., of Chadds Ford, Pa., U.S.A., announced today that they have expanded their drug discovery partnership in oncology, following the successful delivery of an early stage milestone.

The year-old partnership focuses on Jubilant delivering preclinical candidates in the therapeutic area of oncology. Endo owns the late-stage development and commercialization rights for molecules discovered in the partnership. Jubilant derives research funding and success-based development and commercialization milestones.

Commenting on this development, Sri Mosur, CEO & President, Global Drug Discovery & Development said: "We are pleased that we could deliver early success to the discovery portfolio efforts at Endo Pharmaceuticals and this expansion is a testimony to Jubilant's focus in building world class oncology capabilities, among other therapeutic areas. This collaboration further reinforces the concept of globally leveraged R&D that creates a platform for scientists from Endo and Jubilant to collaborate in finding affordable remedies for cancer patients worldwide."

"We have been impressed by the quality of the science and the progress made to date by the Jubilant team on our ongoing oncology discovery program, said Dr. Ivan Gergel, M.D, Executive Vice President of R&D at Endo Pharmaceuticals. "Expanding our relationship in this important therapeutic area is consistent with our strategy of building Endo's pipeline using a virtual discovery approach, in conjunction with our in-licensing efforts."

About Jubilant Biosys

Jubilant Biosys Ltd.
'/>"/>

SOURCE Jubilant Biosys Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Jubilant and BioLeap Announce New Partnership in Drug Discovery
2. Jubilant Biosys Launches Legend NGSS(TM) Advanced Software Solution for High-Throughput Drug Molecule Screening
3. Jubilant to Work With Endo Pharmaceuticals on Drug Development
4. DiscoveRx Corp. & Jubilant Biosys Limited Announce Co-Marketing Agreement for Screening Services
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
9. ConforMIS Moves Headquarters to Expanded Facilities in Burlington, MA
10. BioLife Solutions Expands Scientific Advisory Board
11. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014  Spherix Incorporated (Nasdaq: SPEX) -- an intellectual ... monetization of intellectual property, announced today that the ... Uniden in the U.S. District Court for the ... has been rescheduled for November 10, 2014.  This ... The Court Order setting the Markman date was ...
(Date:10/1/2014)... 2014 As the world takes its first ... doubt that this century would mark the beginning of a ... medicine science. The fact that the world is experiencing a ... the scientific community. Almost half of these chronic conditions are ... prevented with medical care and intervention. While the world is ...
(Date:10/1/2014)... Calif. (PRWEB) September 30, 2014 ... the initial round of grants for the Brain ... undertaking that aims to develop and revolutionize new ... functions of the human brain. This first round ... fiscal year 2014 was allocated to more than ...
(Date:10/1/2014)... New applications of structures and materials ... in nature over millennia are featured in a ... applications in biophotonics in the October issue of the ... published by SPIE, the international society for optics and ... peer-reviewed articles are accessible via open access. , “Biomimetic ...
Breaking Biology Technology:Markman Hearing Date for VTech and Uniden Litigation Now Set for November 10, 2014 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 3NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3
... Ltd. (OTCQB: DROP), the parent company of FUSE Science, Inc. ... superstar Tiger Woods that will feature FUSE Science as the ... Science Adam Adler are set to conduct their first interview ... at 12:30 p.m. during an exclusive interview with Darren Rovell. ...
... WaferGen Biosystems, Inc. (OTCBB:WGBS), an emerging genomic analysis ... nine months ended September 30, 2011 and announced a ... SmartChip System. "During the third quarter of ... the rapidly changing needs of the Life Sciences Research ...
... Phase I Single Dose Study Data ... Convergence Pharmaceuticals Limited ("Convergence"), the company focused ... medicines, today announces that the multiple ascending dose Phase ... channel blocker CNV2197944, for the treatment of chronic pain ...
Cached Biology Technology:Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement! 2WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 2WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 3WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 4WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 5WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 6WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 7WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 8Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 2Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 3Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 4
(Date:9/30/2014)... of Health (NIH) awarded Lawrence Livermore National Laboratory ... array system that will enable researchers to better ... and scale. , LLNL,s grant-funded project is part ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative ... understanding of the human mind and uncover ways ...
(Date:9/30/2014)... can live in almost any aquatic environment on Earth, ... many species are pushed to the limit. The amount ... prove critical for how different species cope in the ... University of Gothenburg, published in the scientific journal ... change continues apace thanks to increasing levels of greenhouse ...
(Date:9/30/2014)... you want your doctor to know what goes wrong with ... good idea to know what "normal" actually is. That,s where ... of the FASEB Journal comes in. ... transcriptomea key set of molecules that can help scientists "see" ... time. What,s more, they found never-before-detected gene activity and that ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3Shape up quickly -- applies to fish, too! 2Scientists identify which genes are active in muscles of men and women 2
... keyhole surgery can be reduced by giving the surgeons a ... with their operating instruments. This is made possible by designing ... feedback signals to the handle held by the surgeon. Delft ... a working prototype for this. Grasp force , ...
... (NYSE Amex: WYY ), a specialist ... announced that Daniel E. Turissini, WidePoint,s CTO, will ... Protection and Management Symposium on February 3, 2011 ... the Federation for Identity and Cross-Credentialing Systems (FiXs). ...
... Asthma is one of the world,s most common chronic diseases, ... by 2025 there could be an additional 100 million people with ... to changing environmental or lifestyle factors, and over the last 15 ... published in the in the February 2011 issue of the ...
Cached Biology News:New training instrument allows surgeon to feel grasp force in keyhole surgery 2WidePoint Corporation Sponsors Identity Protection and Management Symposium, February 3, 2011 2WidePoint Corporation Sponsors Identity Protection and Management Symposium, February 3, 2011 3More research needed on diet and environmental influences on childhood asthma 2More research needed on diet and environmental influences on childhood asthma 3
... two color staining method for labeling DNA ... apoptotic cells by flow cytometry. The kit ... measuring apoptosis in cells including: positive and ... washing, reaction and rinsing buffers for processing ...
... is a 2-color staining method for labeling ... detect apoptotic cells by flow cytometry. The ... for measuring apoptosis in cells including positive ... performance; washing, reaction and rinsing buffers for ...
... The super cooling coil, Trans-Blot ... native enzyme, high-intensity, and extended ... with the Trans-Blot cell. Use ... requires connection to an external ...
... a wide range of next-generation features into ... new standard for flexible laboratory solutions. It ... including pipetting, dilution, dispensing, and integrations ... powerful and flexible as it is efficient ...
Biology Products: